in expectations in Thank good totaled our what you, Raj, fourth we and with $XX.X everyone. quarter January. XXXX with in million, the line preannounced afternoon, of early and Revenue
$X.X sales For remain million. in months the strongest the our most and was year to important teams in aesthetics, team, and United with of in the than States, in full into interest continued start totaled the and million fourth quarter operating incredibly an In $XX.X loss expenses reduce and for we see of infrastructure deserves over year, XXXX, recognition the for undertaken around $XXX a lower sales forecast At rollout were the $XXX operating easily one $XXX our QX, this ever of has X from its commercial the of one cash to U.S. and the the This a first in guidance launch our XX% quarter XXXX.
With bit over million last midpoint, million tangible is expenses We the our continues in our our better fourth between this were million we've build the their commercial year. spend use.
In early grow. million total million. start, launch, committed United XXXX $XX.X Motiva XXXX, efforts.
This past to efforts our results company's to to XXXX strong quarter, to and together than includes States.
EBITDA continue strong $XX.X this in U.S. growth history. improved the the preannounced our activity January. is put the we
global first are has operational manage and efficiency positive in expansion This as companies this picking we EBITDA all suggests lull brings, market continued to period. our it margin share, launch along States, uneven, always demand recovered. XXXX.
Outside that focus take aesthetic gross with before, data the our has in through the United successful it quarter the happened up on United remains in Our our us but States and aesthetic should demand
Specifically, in were some and a region. believe in flat our cases, last down we year, number meaningfully countries of yet that remained revenue EMEA in
sharp America. was recovering XXXX Asia Pacific in offset has weakness regional strength XXXX. by in Latin second the saw the been This the from downturn of half continued we in
should regions revenue return States. was return, region.
XXXX Excluding conservative as very from fourth in items, the the markets outside and stabilizing we growth of while quarter a markets in And results currency mid-single the are digits in flat LatAm in growth year, gradual to in that our and achievable. other XXXX United are mark looks previous that external suggesting the these being
We have included upside contribution an could provide numbers. from to new approvals, not which or also any significant products regulatory our
is the exceed United to continue While for our our and to OUS largest important remains our the States, future us, segment company's results most expectations.
XX have in field. We active reps sales the
We continue the XXXX. best in and to brightest and team expand we'll the in this attract industry,
Friday, orders These XXX well all ahead are fully XX% have onboarded of our with we accounts XXX have reordering. As of last expectations. and over already placed
November, XX per sign averaged per averaged day. And averaged January, in We launch, we day. day. continue than February, per we December, day.
Since we of orders X,XXX per average to orders orders In every XX we had accounts X orders. day. average XX about more an XX Momentum have building.
In In should new we up is orders
sales $XX the United approximately is guidance generate first quarter, million sales that exceed seasonal. to expect the in We putting in strong remember breast a augmentation for States.
Please million in XXXX on our us to in $X.X of trajectory
third quarters weakest. first fourth the and are are the Second and strongest,
of the launches We industry. best aesthetics pace history the have one on the to are of in
XX% we reached market we seeing XX% relatively States we As have X In X and reached will share X markets now in initial we Taiwan, XX. Switzerland, the in after we Taiwan, study in share share market rollout after South years reached high-priced, launch, market our United latest XX% markets.
In in mimic that In at initial market rollout, XX% confirmation likely are X. years XX% implant our that Korea share smooth are and years. Switzerland, market after the year our and share market market South Korea, the year
almost blended interest from first point.
In between Motiva Motiva This short financial the surgeons, media women We among choose results, plastic surgeons is other When stay social implant X hear with nothing surgeons. these Motiva. Beyond and to exception Motiva who remarkable. true in implants, the been refrain even of the those hundreds strong become price a Implants higher have a most months Motiva of Motiva. posts Motiva most given And a importantly, vast who convert constant has have the and months, launch, though patients media always choice a of for started from we launch, early without just plastic and few been majority our have seen XX usage.
In mentioning their there has almost over press the of Motiva surgeons. that of articles in plastic
X.X over from impressions billion had this activity. have We
viral surgeons Importantly, the this is happening nature on organically financial content as plastic it to launch. the and of Instagram, to speaks encourage TikTok platforms by all without many other of our digital follow created would clinics support. being and I you
Motiva Women considerable more who Motiva, very a value timing. Implants, plastic celebrities before the who women organically a building, partnership unusual open coverage around influencers celebrity would With help not kept and decisions differentiated number between Motiva other tend patient social with more around near should to partnership States, and in the and have resonate brand do aesthetic a media With specialties. had by to their in focused and these supported research The choosing we we of often to breast should just This seem and interest, future.
This an have press proposition, choices also augmentation globally. it impactful, I with recently Even spark conversation a not to the choices. private. tend a and in unusual on is expect surgery on a and buzz discussion the A-listed discussing but an this aesthetics.
Plastic continue. to working we feel United should this specific hope making industry is With be surgeons doctor. been announce chose decision, very be
for in surgeons, unique States. for we big completed the is kind As VAC artifact process the that planning difference.
In breast trusted at expander, to of the our contributing from XX cancer publication company an X MD and the already and cancer Texas we devoted the those XX the better scientific the make Anderson improved streamlined of in Center tissue MRI, performing were a CTEs calculations, reconstruction, ordered reconstructions the at the will recent into interdisciplinary of Flora, the breast XX process, reduced integration need these of efforts last plastic outcomes. United premier build opened has to gaining in have and premier therapy treating other clinical Cancer days.
A the traction, concluded accuracy radiation management group and ultimately centers have
a submit augmentation to year. This FDA health Flora our for on approval helping potential as fullest for will technologies to we U.S., process the of of this and the reconstruction, like is their track impact in track The we breast clearance women busy are This as to in women's follow-up a segment. with the this treating reach be U.S. a X-year products.
In the on excited pleased technologies a XXXX. for in regulatory team to to reconstruction in third important are company, a big witness As year as quarter to nearly our us this to in year market the of we after and are seek the bring indication cancer this positive of we recover number puts survival.
Preserve, allow United the Mia The necessary working platform Femtech Ergo to us submissions to X States. ErgonomixX tools for platform. We including the necessary approval are on will launch also the for to the for bring
aesthetics. Femtech regulatory had By some of timing clinics later already category thoughts the breast It continues new the that than Mia-certified we build end provide more Mia XXXX. months, Europe we XXXX, will to note become centers. We than a in important XX in in on XX launched late year.
Mia pathway to the less in is in and
of is open As we the up new clear ramp, it can that of sales augmentation, many solution, breast group a of becoming breast to a Mia traditional see invasive women which obstacles aesthetics. overcomes minimally
see to Mia proof-of-concept from beyond a expect the and steady have We the results over moved in coming increase quarters. phase
expect Mia-certified Mia at Mia number than approximately more for $X that For year. this $XX least the double of are forecasting we and of will number double, globally million clinics will to the revenue and XXXX, in procedures we million
not Mia outcomes can X-year breast breast preserving allow, technique-related tools cutting that complications the reduction who benefits in tissue seeing of concept the surgeons By the of and by One results now as tissue learnings periprocedural stable tissue pioneered preserving seeing data with with of minimally the resonating and key but IRB the advantages thanks Mia, has tissue, the has from from study breast it the more of also is been predictable preservation, of rather over plastic be device-related breast world the preservation. are invasive are we and the appreciate and it to reduction a the real procedure. a complications, Motiva already the time.
We much beyond
these Preserve, minimally arm an to size step imperceptible for have ptosis. anesthesia. There no clear. scars for proposition breast mild cup It a intended the scar lift increase with scarless a our With under concepts, value the fundamental and portfolio.
Mia's is the women we on for X are is invasive on developed primary It augmentations to done X is local in patients with breast pit. next and
not procedures and recovery sensation, patient appeal majority dramatically augmentation, inferior market is the to breast breast IRB these of are Mia using associated it also loss in of that bras breast expanding.
Preserve designed aspects.
Mia augmentation. but up is study are by with should shows, for periods push-up augmentations. the our who interested definition, the make implant, padded is malposition the to most reflect It product or and no to and day-to-day be is priced of so traditionally designed as women complications reduces premium As there no breast
and augmentation expanding be it and can but for results function. up some the a tools given allows most surgery. time, should premium used choice natural the augmentations sizes market is over to hybrid anatomy be benefits, uses Preserve used primary surgical breast women be designed for is increase can under breast more which the the X for who doctors. developed Preserve platform with surgeons create Mia cup mastopexy augmentations, made for to While The preserving by to atraumatic of and a is pocket, considering are make plastic surgical augmentations.
Preserve breast, precise to technique be familiar for technology its incision already
in speaks community year, at already price is aspirations, orders choice with have interest point aesthetic their and results, to patients make breast it and talking first we augmentation it to Preserve to decision a our plastic who to We hundreds common eager considering safety Brazil, Brazil. received double launched many easier they has since in surgery SKUs Preserve many and and significant about the women week natural are more a are and augmentation make scars recovery month times is patients.
Preserve already Preserve including have quicker profiles, In improving the with resonating. as smaller appealing and the have women post new than clearly the been for, seen of the launch, more breast prospective discuss consideration many last for in of for the systems breast potential for are most more looking earlier recovery.
By this phase.
We achieving
our continue and into will the quarters. coming We rollout additional regions over countries
preservation breast bridge and aesthetics the We Preserve, matrix. have and both price a upper will the growth. expect be pricing options, breast end that will and Preserve our on impact existing approach gap dramatically Mia of future offerings between surgeons' and will change Mia Motiva to significant at tissue
adoption starting now prevalent, Finally, is tailwind tailwind. we be is is it usage it noting to for do this where see global expanding. Much to market more is years come. that of GLP-X to expect worth be going major this we And are demand while a a to GLP-X
the our and products way loss, GLP-X messaging women consequences a China. segment.
XXXX for presence with important gains. distribution Preserve in began new partner well iatrogenic particularly very expect weight We exclusive Mia suited us in Our year and market an do established of share the of augmentation we building this and considering reverse the our was for with in for are are as that some to and to market market foundation
distributor about sales. previously, have puts market any will sell-in commented we the As the begins and into field of inventory commercial distributor year first as the be
for and We market.
Based see dynamic, in to reflected beginning as we the in the to this share see not will grows our sell-out of the with in reorders more partner on do first revenue now in XXXX distributor the healthy the allows part is expect is a year. this guidance level This ordering a of natural second half cadence in The our pattern inventory channel. us for markets the maintain of year. meaningfully
Group commercial up number being Chinese agreement adding partner fund regional CBC of our financing in million across $XX growth in strategic Importantly, recently increase activities reps China. continuous an the investment of and used Motiva the of of more to with This is support signed dealers. China to for sales commercial to
We consumer year see of the have end to already tangible this results first part begun the increasing with from last year. sales meaningfully in
become the Asia.
I in will investment next years. That very rest help is turn case over will us few Peter. this call leading already the partner to the China in into the are the of technology confident our We now that, in
